Losartan Potassium
Product Images NDC 54868-6117

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 54868-6117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tablets Usp 50 mg Label (6104)

Label for Losartan Potassium 50mg, distributed by Physicians Total Care, Inc. The label includes the NDC code 54068-6104-0, lot number 0000, and an expiration date of 01/60. Manufactured by Teva Pharmaceuticals, Israel. A barcode is also present on the label.*

FDA Label Image

Losartan Potassium Tablets Usp 100 mg Label (6107)

Packaging label for Losartan Potassium 100 mg tablets showing the labeler as Physicians Total Care, Inc. The label includes an NDC number, lot number, and an expiration date, along with a barcode and the manufacturer location in Jerusalem, Israel.*

FDA Label Image

Losartan Potassium Tablets Usp 25 mg Label (6117)

Losartan Potassium 25 mg tablet bottle label from Physicians Total Care, Inc. The label includes product strength (25 mg), quantity (39 tablets), and a caution that federal law prohibits dispensing without a prescription. It shows a barcode, NDC 54868-611-27, and lot and expiration information.*

FDA Label Image

Chem Structure For Losartan Potassium (B0445fa2 0e1a 4978 B49a B52fd494d568 01)

Chemical structure of Losartan Potassium, showing its molecular arrangement including a chlorinated imidazole ring, biphenyl group, and attached potassium ion (K+).*

FDA Label Image

Figure 1 (B0445fa2 0e1a 4978 B49a B52fd494d568 02)

A line graph depicting the percentage of patients with a primary endpoint over study months, comparing Losartan potassium and Atenolol. The graph shows adjusted risk reduction of 13% for Losartan potassium with statistical significance (p=0.021). The x-axis represents study months (0 to 66), and the y-axis represents percentage of patients.*

FDA Label Image

Figure 2 (B0445fa2 0e1a 4978 B49a B52fd494d568 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months between Atenolol and Losartan potassium. The graph shows lower stroke rates for Losartan potassium, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (B0445fa2 0e1a 4978 B49a B52fd494d568 04)

A comparative forest plot illustrating the hazard ratios with 95% confidence intervals for primary composite events and fatal/non-fatal stroke rates between Losartan Potassium and Atenolol. Data are stratified by patient demographics and clinical characteristics including age, gender, race, presence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The plot visually compares efficacy outcomes between the two treatments using proportional symbols to sample size.*

FDA Label Image

Figure 4 (B0445fa2 0e1a 4978 B49a B52fd494d568 05)

A line graph comparing the percentage of patients with an event over a 48-month period for Losartan Potassium versus placebo. The graph shows risk reduction of 16.1% with Losartan Potassium, including a p-value of 0.022, with time in months on the x-axis and percentage of patients with event on the y-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.